New Long-Acting HIV shot shows promise for kids and teens
NCT ID NCT06749054
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a long-acting HIV medicine called lenacapavir (Sunlenca®) in 12 adolescents and children with HIV who have tried other treatments. Participants take lenacapavir as pills and injections along with their other HIV drugs. The goal is to see if the combination is safe, tolerable, and effective at controlling the virus.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
lenacapavir (Sunlenca®) given as pills and injections, plus an optimized background regimen of other HIV medicines
What this could lead to
If it works, this could provide a long-acting, easier-to-take option for children and teens with HIV who have limited treatment choices.
What could go wrong
This is a small, early-phase study with only 12 participants, so results may not apply to everyone. Side effects or lack of effectiveness are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV-1-INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Be Part Research Pty (Ltd)
RECRUITINGPaarl, 7626, South Africa
-
CRISMO Research Centre
RECRUITINGGermiston, 1401, South Africa
-
Clinical Research Institute of South Africa (CRISA)
RECRUITINGKwaDukuza, 4449, South Africa
-
Durban International Clinical Research Site, Enhancing Care Foundation
RECRUITINGKwaZulu - Natal, 4093, South Africa
-
FAMCRU
RECRUITINGCape Town, 7505, South Africa
-
Grady Health System, Ponce De Leon Center
RECRUITINGAtlanta, Georgia, 30308, United States
-
Perinatal HIV Research Unit (PHRU)
WITHDRAWNSoweto, 2013, South Africa
-
Rahima Moosa Mother and Child Hospital
RECRUITINGJohannesburg, 2112, South Africa
-
Wits RHI Shandukani Research Centre CRS
RECRUITINGJohannesburg, 2038, South Africa